Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker study of chemo-immunotherapy response in driver-mutated advanced non-small cell lung cancer
NL-OMON54889Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by University Medical Center Groningen. Primary endpoint: Progression-free survival-based response classification. Started Sep 2020; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON54889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54889.